Vanguard Capital Management
XFOR icon

Vanguard Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Vanguard Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4M Buy
3,715,859
+218,247
+6% +$895K ﹤0.01% 2527
2026
Q1 		$14.4M Buy
+3,497,612
New +$13.1M ﹤0.01% 2522

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $140M AUM
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management's XFOR Position: Q2 2026 in Review

Vanguard Capital Management increased its X4 Pharmaceuticals (XFOR) stake by 6.2% in Q2 2026, buying an estimated $895K and bringing the position to 3,715,859 shares worth $17.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2527.

Vanguard Capital Management first reported a position in XFOR in Q1 2026 and has held it in 2 quarters since. 88 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Vanguard Capital Management held 3,715,859 shares of X4 Pharmaceuticals worth $17.4M as of Q2 2026.
  • Vanguard Capital Management bought 218,247 X4 Pharmaceuticals shares in Q2 2026, an estimated $895K.
  • X4 Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2527 holding.
  • Vanguard Capital Management first reported a position in X4 Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 88 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.